Akoya Biosciences Appoints Marilee Moy as Chief People Officer
21 January 2022 - 12:05AM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today announced the appointment of Marilee Moy as
Chief People Officer. Ms. Moy has more than 30 years of HR
leadership experience at high-performing life sciences and
technology companies. She will be instrumental in defining and
executing Akoya’s human resource strategy as the company enters a
new phase of global growth.
Ms. Moy joins Akoya with deep operational and strategic
expertise in managing human resources for rapidly growing life
sciences companies. She has worked at life sciences and technology
companies ranging from start-ups to international, public
companies. Prior to joining Akoya Biosciences, she led human
resources at Talis Biomedical Corporation during a period of rapid
growth, and prior to that was VP of People at Counsyl (now part of
Myriad Genetics Inc.). She has held HR leadership roles focused on
growing and developing talent and culture at Genentech Inc.,
Abbott, Johnson & Johnson, and Nikon Precision Inc. Ms. Moy
holds a B.A. from Boston College, an M.B.A from Golden Gate
University.
“Marilee brings to Akoya a track record of deep experience as a
thoughtful and strategic HR executive, whose leadership of a cross
functional team will touch on all aspects of our business,” said
Brian McKelligon, Chief Executive Officer of Akoya. “Well-developed
human resource programs and processes that support Akoya’s
continued high performance across all employee levels throughout
the world are critical to the successful implementation of Akoya’s
next phase of growth.”
Akoya is a pioneer in the rapidly emerging field of spatial
phenotyping, a transformational new application that is giving
unprecedented context to cell-cell interactions within tissue
biology. Understanding spatial biomarker signatures within the
framework of spatial phenotyping has the potential to unlock an
explosion of new applications in medicine and research, such as the
ability to segment patient populations based on immune
interactions, development of spatial diagnostic assays, drug
discovery, and design or identification of personalized therapeutic
interventions.
“As a member of our senior leadership team, I am particularly
interested in the development of the company’s strategic and
organizational plans from the perspective of its impact on
employees,” said Ms. Moy. “Translating Akoya’s vision and tactical
business strategy into HR initiatives that support the hiring,
onboarding, cultural well-being, talent optimization, and
management of a rapidly expanding global organization, while
complying with employment regulations across geographies, is my
responsibility and a priority for me.”
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research via its key platforms:
PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more
about Akoya, visit www.akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciences, Inc.investors@akoyabio.com
Media Contact:Michelle LinnBioscribe,
Inc.774-696-3803 michelle@bioscribe.com
A photo accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2dc5696e-3ca2-455c-9b2e-a75ad9ebe366
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2023 to Apr 2024